News Article | December 16, 2016
— Age Related Macular Degeneration - Companies Involved in Therapeutics Development are 3SBio Inc, AC Immune SA, Achillion Pharmaceuticals Inc, Aciont Inc, Acucela Inc, AdAlta Ltd, Adverum Biotechnologies Inc, Aerie Pharmaceuticals Inc, Aerpio Therapeutics Inc, Alimera Sciences Inc, Alkeus Pharmaceuticals Inc, Allergan Plc, Allinky Biopharma, Alteogen Inc, Amakem NV, Amarna Therapeutics BV, Ampio Pharmaceuticals Inc, Amyndas Pharmaceuticals LLC, ANP Technologies Inc, Apellis Pharmaceuticals Inc, Apexigen Inc, Applied Genetic Technologies Corp, Astellas Pharma Inc, Benitec Biopharma Ltd, Biokine Therapeutics Ltd, BioMAS Ltd, Biomics Biotechnologies Co Ltd, Biophytis SAS, BLR Bio LLC, Boehringer Ingelheim GmbH, Caladrius Biosciences Inc, Catalyst Biosciences Inc, Cell Cure Neurosciences Ltd, Cell Medica Ltd, Charlesson LLC, Chong Kun Dang Pharmaceutical Corp, Cipla Ltd, Clanotech AB, Clearside BioMedical Inc, Coherus BioSciences Inc, Colby Pharmaceutical Company, Crinetics Pharmaceuticals Inc, Critical Pharmaceuticals Ltd, Daiichi Sankyo Company Ltd, Diffusion Pharmaceuticals Inc, Dong-A Socio Holdings Co Ltd, Eleven Biotherapeutics Inc., Elsalys Biotech SAS, Exonate Ltd, F. Hoffmann-La Roche Ltd, FirstString Research Inc, Foamix Pharmaceuticals Ltd, Formycon AG, Gene Techno Science Co Ltd, Genentech Inc, GenSight Biologics SA, GlaxoSmithKline Plc, Graybug Vision Inc, Grupo Ferrer Internacional SA, HanAll Biopharma Co Ltd, Huabo Biopharm Co Ltd, iCo Therapeutics Inc., Icon Bioscience Inc, Iconic Therapeutics Inc, Inception Sciences Inc, Innovent Biologics Inc, Intellect Neurosciences Inc, International Stem Cell Corp, Ionis Pharmaceuticals Inc, Jeil Pharmaceutical Co Ltd, Johnson & Johnson, Kala Pharmaceuticals Inc, Kodiak Sciences Inc, Lead Discovery Center GmbH, LeadArtis SL, M's Science Corp, Mabion SA, MacuCLEAR Inc, MeiraGTx Ltd, Mitotech SA, Mitsubishi Tanabe Pharma Corp, Mor Research Application Ltd, Navigen Pharmaceuticals Inc, Navya Biologicals Pvt Ltd, Neovacs SA, Neumedicines Inc, Neuroptis Biotech, Novartis AG, NovelMed Therapeutics Inc, Ocular Therapeutix Inc, Ohr Pharmaceutical Inc, Omeros Corp, Ophthotech Corp, Oxford BioMedica Plc, PanOptica Inc, Pfenex Inc, Pfizer Inc, Precision Ocular Ltd, Promedior Inc, pSivida Corp, QLT Inc, Ra Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, RegenxBio Inc, Retrotope Inc, Ribomic Inc, RXi Pharmaceuticals Corp, Samumed LLC, SanBio Inc, Santen Pharmaceutical Co Ltd, SciFluor Life Sciences LLC, Stealth BioTherapeutics Inc, Sucampo Pharmaceuticals Inc, Sumitomo Dainippon Pharma Co Ltd, Sun Pharma Advanced Research Company Ltd, TRACON Pharmaceuticals Inc, TWi Pharmaceuticals Inc, Tyrogenex Inc, Wellstat Ophthalmics Corp and Xbrane Biopharma AB. Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in depreciation of the macula that may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity etc. Symptoms include development of blind spot and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy and medication such as anti-angiogenic drugs. The Age Related Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 33, 11, 109 and 31 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 15 and 2 molecules, respectively. Age Related Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Inquire more about this research at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=786897 Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. • The pipeline guide provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration (Ophthalmology). • The pipeline guide reviews pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Age Related Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Age Related Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology) • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Age Related Macular Degeneration (Ophthalmology). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Age Related Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. For more information, please visit http://www.reportsnreports.com/
News Article | November 16, 2016
The report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Schizophrenia - Pipeline Review, H2 2016 addition with 118 market data tables and 17 figures, spread across 349 pages is available at http://www.reportsnreports.com/reports/747736-schizophrenia-pipeline-review-h2-2016.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis Alkermes Plc ,Angita B.V. ,Astellas Pharma Inc. ,Athersys, Inc. ,Avanir Pharmaceuticals, Inc.,Avineuro Pharmaceuticals, Inc.,BCWorld Pharm Co. Ltd.,BioCrea GmbH BioHealthonomics Inc ,Boehringer Ingelheim GmbH,Braeburn Pharmaceuticals, Inc.,Bristol-Myers Squibb Company,Critical Pharmaceuticals Limited,Curemark, LLC ,Delpor, Inc. ,Denovo Biopharma, LLC,Echo Pharmaceuticals,B.V.,Egis Gyogyszergyar Nyrt,Evotec AG ,F. Hoffmann-La Roche Ltd.,Fabre-Kramer Pharmaceuticals, Inc. Inquire before buying http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=747736this is a premium report price at US$2000 for a single user PDF license).
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 139.92K | Year: 2015
Age-related macular degeneration (AMD) is the leading cause of blindness in those aged over 50, causing blurring, distortion and loss of central vision and almost always affects quality of life. There are two main types of AMD, wet and dry. Wet AMD is most severe but more treatable and occurs in about 1 in 10 cases. However it causes severe visual loss over a short time, sometimes just months or even hours / days if there is a haemorrhage. Current treatment requires monthly injections into the eye, which are unpleasant for the patient and carry a risk of infection. This project aims to prepare a novel, sustained release treatment to reduce the necessary frequency of injections, improving the patient experience and reducing the risks and costs of treatment.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 341.42K | Year: 2011
To address unmet clinical needs, protein-based medicines must be manufactured so as to overcome many limitations including their propensity to degrade and to clear rapidly from blood circulation. Our consortium has developed two proprietary technologies that are based on clinically proven strategies and address the inherent limitations of protein-based medicines. Critical Pharmaceuticals (CP) have developed novel biodegradable microparticles able to encapsulate proteins for prolonged continuous release. PolyTherics (PT) have developed technologies for site-specific PEGylation of proteins that result in the extension of their half-life while in circulation and an increase in their pharmaceutical stability. We propose to combine these technologies to produce high value products with enhanced performance where the combined technology is superior to the technologies used separately.
Critical Pharmaceuticals | Date: 2016-04-27
A process for preparing microparticles comprising a biologically active material and a polymer and having a mean particle size expressed as the volume mean diameter (VMD) of from 10 to 500 m, wherein the biologically active material is substantially insoluble in the polymer, which process comprises:a. contacting a mixture of the biologically active material or a precursor thereof , the polymer or a precursor thereof and a processing aid with a supercritical fluid which is capable of swelling the polymer under temperature and pressure conditions necessary to maintain the fluid in a supercritical state;b. allowing the supercritical fluid to penetrate and liquefy the polymer, whilst maintaining the temperature and pressure conditions so that the fluid is maintained in a supercritical state;c. releasing the pressure to precipitate microparticles comprising the biologically active agent and the polymer.
Critical Pharmaceuticals | Date: 2014-10-07
There is provided a supercritical fluid-based process for preparing a solid polymer matrix containing a core material, wherein the process includes the step of mixing the polymer, core material and supercritical fluid in a mixing vessel, followed at least one cycle of, without recovering the solid polymer matrix, (i) converting the supercritical fluid in the mixing vessel to a sub-critical state, and then (ii) returning the fluid to the supercritical state, provided that the core material does not comprise any of gonadotropin releasing hormone (GnRH), a GnRH agonist and a GnRH antagonist.
Critical Pharmaceuticals | Date: 2013-11-14
Absorption of a therapeutic agent across a mucosal membrane or the skin can be enhanced using an absorption enhancer comprising a hydroxy fatty acid ester of polyethylene glycol.
Critical Pharmaceuticals | Date: 2015-11-20
A process for preparing microparticles comprising a biologically active material and a polymer and having a mean particle size expressed as the volume mean diameter (VMD) of from 10 to 500 m, wherein the biologically active material is substantially insoluble in the polymer, which process comprises: a. contacting a mixture of the biologically active material or a precursor thereof, the polymer or a precursor thereof and a processing aid with a supercritical fluid which is capable of swelling the polymer under temperature and pressure conditions necessary to maintain the fluid in a supercritical state; b. allowing the supercritical fluid to penetrate and liquefy the polymer, whilst maintaining the temperature and pressure conditions so that the fluid is maintained in a supercritical state; c. releasing the pressure to precipitate microparticles comprising the biologically active agent and the polymer.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 177.86K | Year: 2012
We plan to develop a nasal spray formulation of PTH1-34 for the treatment of osteoporosis using the CriticalSorb absorption enhancer. Osteoporosis is a prevalent disease (effecting 40% of women by age 80), characterised by reduced bone density and increased risk of fracture, particularly of the hip, wrist and spine, at a cost to the NHS of >£2bn per annum. PTH1-34 is the only drug available that stimulates the formation of new bone, but currently needs to be injected every day. Not only is this invasive method of drug administration not well liked by patients, but it is a complicated multi-step process and as osteoporosis patients are elderly they can find it difficult. The nasal spray we develop is expected to improve ease of use, increase patient compliance with the treatment regimen and increase efficacy with the aim of improving treatments and reducing healthcare costs.
Agency: European Commission | Branch: H2020 | Program: SME-1 | Phase: NMP-25-2014-1 | Award Amount: 71.43K | Year: 2015
Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration This feasibility study is to verify the technical and economic viability of a sustained release bevacizumab product (SR Bevacizumab) to improve the safety, cost-effectiveness and patient acceptability for the treatment of wet age-related macular degeneration (AMD). AMD is the leading cause of blindness in those aged over 50 and causes blurring, distortion and loss of central vision and almost always affects quality of life. Prototype SR Bevacizumab products will be manufactured using CriticalMix, an advanced manufacturing and processing technology developed by Critical Pharmaceuticals, which will encapsulate bevacizumab in biodegradable polymers suitable for sustained release of the drug in the eye.